Improving antibiotic choices for cancer patients with reported penicillin allergies
Optimizing antibiotic selection in hematologic malignancy patients with reported beta-lactam allergy
This study is looking to help patients with blood cancers who are at risk for infections by finding better ways to choose antibiotics, especially for those who might have been wrongly labeled as allergic to certain medications, so they can receive safer and more effective treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11077256 on NIH RePORTER |
What this research studies
This research focuses on patients with hematologic malignancies who are at high risk for infections and complications due to prolonged antibiotic use. It aims to optimize antibiotic selection by addressing the common issue of inaccurate beta-lactam allergy labels, which can lead to the use of less effective and more harmful antibiotics. The study will explore interventions such as patient history reviews, skin testing, and oral challenges to safely delabel patients who are inaccurately labeled as allergic. By improving antibiotic stewardship, the research seeks to enhance treatment outcomes for these vulnerable patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematologic malignancies who have reported beta-lactam allergies.
Not a fit: Patients without hematologic malignancies or those who do not have a reported beta-lactam allergy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective antibiotic treatments for cancer patients, reducing complications and improving survival rates.
How similar studies have performed: Previous studies have shown that interventions to delabel antibiotic allergies can significantly improve antibiotic use and clinical outcomes in hospitalized patients.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Lautenbach, Ebbing — University of Pennsylvania
- Study coordinator: Lautenbach, Ebbing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.